Biomarkers for cognitive impairment and dementia in elderly people

Joshua A. Sonnen, Kathleen S. Montine, Joseph F. Quinn, Jeffrey A. Kaye, John CS Breitner, Thomas J. Montine

Research output: Contribution to journalReview article

Abstract

The threat of a looming pandemic of dementia in elderly people highlights the compelling need for the development and validation of biomarkers that can be used to identify pre-clinical and prodromal stages of disease in addition to fully symptomatic dementia. Although predictive risk factors and correlative neuroimaging measures will have important roles in these efforts, this Review describes recent progress in the discovery, validation, and standardisation of molecular biomarkers-small molecules and macromolecules whose concentration in the brain or biological fluids can aid diagnosis at different stages of the more common dementing diseases and in the assessment of disease progression and response to therapeutics. An approach that efficiently combines independent information from risk-factor assessment, neuroimaging measures, and biomarkers might soon guide clinicians in the early diagnosis and management of cognitive impairment in elderly people.

Original languageEnglish (US)
Pages (from-to)704-714
Number of pages11
JournalThe Lancet Neurology
Volume7
Issue number8
DOIs
StatePublished - Aug 1 2008
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Biomarkers for cognitive impairment and dementia in elderly people'. Together they form a unique fingerprint.

  • Cite this

    Sonnen, J. A., Montine, K. S., Quinn, J. F., Kaye, J. A., Breitner, J. CS., & Montine, T. J. (2008). Biomarkers for cognitive impairment and dementia in elderly people. The Lancet Neurology, 7(8), 704-714. https://doi.org/10.1016/S1474-4422(08)70162-5